medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2015, Number 6

<< Back

Salud Mental 2015; 38 (6)

Inmunoprotección activa contra cocaína

Salazar-Juárez A, Barbosa MS, Jurado N, Munguía A, Antón B

Language: Spanish
References: 55
Page: 441-447
PDF size: 169.16 Kb.


ABSTRACT

Introduction The classic pharmacopoeia used to attenuate cocaine dependence has proved a poor therapeutic efficacy. Based on this discouraging clinical and therapeutic panorama, since more than a decade, various researchers have developed new therapeutic strategies against cocaine addiction. These new experimental strategies are based on the structural design and synthesis of therapeutic vaccine formulations against cocaine addiction.
Objective To describe the development and therapeutic evaluation of active immunization against cocaine.
Method A bibliographical search was made using PubMed, using as descriptors the words “Cocaine” and “Vaccine.” 155 articles were obtained which were used for these review 46 items.
Results At preclinical level, active vaccination generates high levels of antibodies capable of recognizing with high specificity the cocaine present in the bloodstream, which attenuates the behavioral changes induced by different doses of cocaine.
Discussion and conclusion Preclinical and clinical results have reinforced “proof of concept” active therapeutic vaccination to pharmacological control to cocaine use relapse in humans, but gave guidelines to the postulation and justification of synthesizing new models of anti-cocaine vaccines for human use. This experimental pharmacological strategy of “immunoprotective” nature has proven an effective treatment that significantly reduces drug-seeking behaviors, both at pre-clinical levels in the rodent model as well as in humans.


REFERENCES

  1. Carrera MR, Meijler MM, Janda KD. Cocaine pharmacology and current pharmacotherapies for its abuse. Bioorg Med Chem 2004;12(19):5019-5030.

  2. Haney M, Kosten TR. Therapeutic vaccines for substance dependence. Expert Rev Vaccines 2004;3(1):11-18.

  3. McMillan DE, Hardwick WC, Li M, Owens SM. Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody. Behav Pharmacol 2002;13(5-6):465-473.

  4. Orson FM, Kinsey BM, Singh RA, Wu Y et al. Vaccines for cocaine abuse. Hum Vaccine 2009;5(4):194-199.

  5. Dickerson TJ, Janda KD. Recent advances for the treatment of cocaine abuse: central nervous system immunopharmacotherapy. AAPS J 2005;7(3):E579-E586.

  6. Kosten T, Owens SM. Immunotherapy for the treatment of drug abuse. Pharmacol Ther 2005;108(1):76-85.

  7. Meijler MM, Matsushita M, Wirsching P, Janda KD. Development of immunopharmacotherapy against drugs of abuse. Curr Drug Discov Technol 2004;1(1):77-89.

  8. Orson FM, Kinsey BM, Singh RA, Wu Y et al. Substance abuse vaccines. Ann N Y Acad Sci 2008;1141(2):257-269.

  9. Kosten TR, Biegel D. Therapeutic vaccines for substance dependence. Expert Rev Vaccines 2002;1(3):363-371.

  10. Martell BA, Mitchell E, Poling J, Gonsai K et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005;58(2):158-164.

  11. Anton B, Leff P. A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 2006;24(16):3232- 3240.

  12. Anton B, Salazar A, Florez A, Matus M et al. Vaccines against morphine/ heroin and its use as effective medication for preventing relapse to opiate addictive behaviors. Hum Vaccine 2009;5(4):214:229.

  13. Bonese KF, Wainer BH, Fitch FW, Rothberg RM et al. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 1974;252(5485):708-710.

  14. Cerny EH, Cerny T. Vaccines against nicotine. Hum Vaccine 2009;5(4):200-205.

  15. Gentry WB, Rüedi-Bettschen D, Owens SM. Development of active and passive human vaccines to treat methamphetamine addiction. Hum Vaccine 2009;5(4):206-213.

  16. Bagasra O, Forman LJ, Howeedy A, Whittle P. A potential vaccine for cocaine abuse prophylaxis. Immunopharmacology 1992;23(3):173-179.

  17. Carrera MR, Ashley JA, Parsons LH, Wirsching P et al. Suppression of psychoactive effects of cocaine by active immunization. Nature 1995;378(6558):727-370.

  18. Carrera MR, Ashley JA, Wirsching P, Koob GF et al. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci USA 2001;98(4):1988-1992.

  19. Carrera MR, Ashley JA, Zhou B, Wirsching P et al. Cocaine vaccines: antibody protection against relapse in a rat model. Proc Natl Acad Sci USA 2000;97(11):6202-6206.

  20. Carrera MR, Kaufmann GF, Mee JM, Meijler MM et al. Treating cocaine addiction with viruses. Proc Natl Acad Sci USA 2004;101(28):10416- 10421.

  21. Ettinger RH, Ettinger WF, Harless WE. Active immunization with cocaine-protein conjugate attenuates cocaine effects. Pharmacol Biochem Behav 1997;58(1):215-220.

  22. Fox BS, Kantak KM, Edwards MA, Black KM et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996;2(10):1129- 1132.

  23. Kantak KM. Anti-cocaine vaccines: antibody protection against relapse. Expert Opin Pharmacother 2003;4(2):213-218.

  24. Fox BS. Development of a therapeutic vaccine for the treatment of cocaine addiction. Drug Alcohol Depend 1997;48(3):153-158.

  25. Landry DW. Immunotherapy for cocaine addiction. Sci Am 1997;276(2):42-45.

  26. Kosten TR, Rosen M, Bond J, Settles M et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002;20(7-8):1196- 1204.

  27. Kosten TR, Domingo CB, Shorter D, Orson F et al. Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend 2014; 140(1):42-47.

  28. Ino A, Dickerson TJ, Janda KD. Positional linker effects in haptens for cocaine immunopharmacotherapy. Bioorg Med Chem Lett 2007;17(15):4280-4283.

  29. Kinsey BM, Jackson DC, Orson FM. Anti-drug vaccines to treat substance abuse. Immunol Cell Biol 2009;87(4):309-314.

  30. Kinsey BM, Kosten TR, Orson FM. Active immunotherapy for the Treatment of Cocaine Dependence. Drugs Future 2010;35(4):301-306.

  31. Johnson MW, Ettinger RH. Active cocaine immunization attenuates the discriminative properties of cocaine. Exp Clin Psychopharmacol 2000;8(2):163-167.

  32. Koetzner L, Deng S, Sumpter TL, Weisslitz M et al. Titer-dependent antagonism of cocaine following active immunization in rhesus monkeys. J Pharmacol Exp Ther 2001;296(3):789-796.

  33. Wise RA, Ranaldi R. Cocaine vaccines revisited. Nat Med 1996;2(10):1073-1074.

  34. Kantak KM, Collins SL, Bond J, Fox BS. Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology (Berl) 2001;153(3):334-340.

  35. Kantak KM, Collins SL, Lipman EG, Bond J et al. Evaluation of anti- cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl) 2000;148(3):251-262.

  36. Hicks MJ, De BP, Rosenberg JB, Davidson JT et al. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol Ther 2011;19(3):612-619.

  37. Koob GF, Hicks MJ, Wee S, Rosenberg JB et al. Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus. CNS Neurol Disord Drug Targets 2011;10(8):899-904.

  38. Matthews QL, Yang P, Wu Q, Belousova N et al. Optimization of capsid- incorporated antigens for a novel adenovirus vaccine approach. Virol J 2008;5(1):98.

  39. Wee S, Hicks MJ, De BP, Rosenberg JB et al. Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. Neuropsychopharmacology 2011;37(5):1083-1091.

  40. Hicks MJ, Kaminsky SM, De BP, Rosenberg JB et al. Fate of systemically administered cocaine in nonhuman primates treated with the dAd5GNE anticocaine vaccine. Hum Gene Ther Clin Dev 2014;25(1):40- 49.

  41. Maoz A, Hicks MJ, Vallabhjosula S, Synan M et al. Adenovirus capsid- based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter. Neuropsychopharmacology 2013;38(11):2170-2178.

  42. De BP, Pagovich OE, Hicks MJ, Rosenberg JB et al. Disrupted adenovirus- based vaccines against small addictive molecules circumvent anti-adenovirus immunity. Hum Gene Ther 2013;24(1):58-66.

  43. Cai X, Whitfield T, Hixon MS, Grant Y et al. Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design. J Med Chem 2013;56(9):3701-3709.

  44. Meijler MM, Kaufmann GF, Qi L, Mee JM et al. Fluorescent cocaine probes: a tool for the selection and engineering of therapeutic antibodies. J Am Chem Soc 2005;127(8):2477-2484.

  45. Reindl M, Hoffmann-Roder A. Antibody recognition of fluorinated haptens and antigens. Curr Top Med Chem 2014;14(7):840-854.

  46. Kosten T, Domingo C, Orson F, Kinsey B. Vaccines against stimulants: cocaine and MA. Br J Clin Pharmacol 2014a; 77(2):368-374.

  47. Kosten TR, Domingo CB. Can you vaccinate against substance abuse? Expert Opin Biol Ther 2013;13(8):1093-1097.

  48. Stitzer ML, Polk T, Bowles S, Kosten T. Drug users’ adherence to a 6-month vaccination protocol: effects of motivational incentives. Drug Alcohol Depend 2010;107(1):76-79.

  49. Matsui K, Friedman H, Klein TW. Cocaine augments proliferation of human peripheral blood T-lymphocytes activated with anti-CD3 antibody. Int J Immunopharmacol 1992;14(7):1213-1220.

  50. Isomura S, Hoffman TZ, Wirsching P, Janda KD. Synthesis, properties, and reactivity of cocaine benzoylthio ester possessing the cocaine absolute configuration. J Am Chem Soc 2002;124(14):3661-3668.

  51. Nielsen DA, Hamon SC, Kosten TR. The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial. Psychiatr Genet 2013;23(6):225-232.

  52. Kinsey BM, Kosten TR, Orson FM. Anti-cocaine vaccine development. Expert Rev Vaccines 2010;9(9):1109-1114.

  53. Shen X, Kosten TR. Immunotherapy for drug abuse. CNS Neurol Disord Drug Targets 2011;10(8):876-879.

  54. Orson FM, Rossen RD, Shen X, Lopez AY et al. Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. Am J Addict 2013;22(2):169-174.

  55. Carrera MR, Trigo JM, Wirsching P, Roberts AJ et al. Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. Pharmacol Biochem Behav 2005;81(4):709-714.




2020     |     www.medigraphic.com